Solaris develops drugs against the E3 ligase family of proteins, implicated in diseases across multiple therapeutic areas. Our lead, a novel oral antidiabetic shown to improve glucose control and insulin responsiveness, is 2 years and $1MM from clinical candidate stage, when it will be an attractive partnering target for global pharmaceutical companies. Potential follow-ons are being considered in oncology, CNS, and anti-infective diseases.